IGF-1 Receptor β/IGF1R Antibody (F-1): sc-390130. Western blot analysis of IGF-IRβ expression in A-431 (A), MCF7 (B), NIH/3T3 (C) and HeLa (D) whole cell lysates.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
IGF-1 Receptor β/IGF1R Antibody (F-1): sc-390130. Western blot analysis of IGF-IRβ expression in A-431 (A), MCF7 (B), NIH/3T3 (C) and HeLa (D) whole cell lysates.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
IGF-1 Receptor α/β/IGF1R CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
IGF-1 Receptor α/β/IGF1R CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
gRNAs encoded by IGF-1 Receptor α/β/IGF1R CRISPR Activation Plasmid (m) and IGF-1 Receptor α/β/IGF1R CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Igf1r transcriptional start site. One or both designs may be available